Symbols / SION Stock $37.78 +2.94% Sionna Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
SION (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael Cloonan M.B.A.
Exch · Country NGM · United States
Market Cap 1.71B
Enterprise Value 1.50B
Income -85.56M
Sales —
FCF (ttm) -45.70M
Book/sh 6.39
Cash/sh 4.79
Employees 59
Insider 10d —
IPO Feb 07, 2025
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -13.48
PEG —
P/S —
P/B 5.91
P/C —
EV/EBITDA -15.24
EV/Sales —
Quick Ratio 22.11
Current Ratio 22.60
Debt/Eq 2.91
LT Debt/Eq —
EPS (ttm) -1.86
EPS next Y -2.80
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-10
Earnings (prior) 2026-05-12
ROA -18.33%
ROE -26.74%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 45.15M
Shs Float 16.80M
Insider Own 6.85%
Instit Own 100.17%
Short Float 17.05%
Short Ratio 10.35
Short Interest 4.74M
52W High 48.45
vs 52W High -22.01%
52W Low 13.51
vs 52W Low 179.64%
Beta —
Impl. Vol. 3.13%
Rel Volume 0.89
Avg Volume 391.80K
Volume 348.25K
Target (mean) $51.60
Tgt Median $54.00
Tgt Low $23.00
Tgt High $63.00
# Analysts 10
Recom Buy
Prev Close $36.70
Price $37.78
Change 2.94%
About

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$51.60
Mean price target
2. Current target
$37.78
Latest analyst target
3. DCF / Fair value
$-18.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$37.78
Low
$23.00
High
$63.00
Mean
$51.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-26 reit Citizens Market Outperform → Market Outperform $63
2026-05-20 down Freedom Broker Buy → Hold $38
2026-05-18 main Stifel Buy → Buy $55
2026-05-13 reit BTIG Buy → Buy $58
2026-05-05 init Wedbush — → Outperform $53
2026-04-28 main Jones Trading Buy → Buy $63
2026-04-27 reit BTIG Buy → Buy $58
2026-03-03 main Guggenheim Buy → Buy $50
2026-03-02 reit BTIG Buy → Buy $58
2026-02-24 init Citizens — → Market Outperform $63
2026-01-14 reit BTIG Buy → Buy $58
2026-01-07 main BTIG Buy → Buy $58
2025-12-23 init LifeSci Capital — → Outperform $60
2025-12-01 down RBC Capital Sector Perform → Underperform $24
2025-11-19 init BTIG — → Buy $50
2025-10-17 init Freedom Broker — → Buy $38
2025-09-08 init Jones Trading — → Buy $46
2025-09-03 init Raymond James — → Strong Buy $45
2025-09-03 init RBC Capital — → Sector Perform $22
2025-03-04 init Stifel — → Buy $32
News
RSS: Latest SION news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-27 THOMPSON PETER A Director — 101 $44.49 $4,493
2026-05-11 THOMPSON PETER A Director — 292,952 $44.58 $13,364,064
2026-05-11 ORBIMED ADVISORS, L.L.C. Unknown — 292,952 $44.58 $13,364,064
2026-04-17 THOMPSON PETER A Director — 55,345 $44.52 $2,472,343
2026-04-17 ORBIMED ADVISORS, L.L.C. Unknown — 55,345 $44.52 $2,472,343
2026-04-16 THOMPSON PETER A Director — 510,583 $44.51 $22,945,044
2026-04-16 ORBIMED ADVISORS, L.L.C. Unknown — 510,583 $44.51 $22,945,044
2026-03-05 FITZPATRICK JENNIFER R Officer — 10,250 $6.11 $62,628
2026-03-05 FITZPATRICK JENNIFER R Officer — 10,250 $33.86 $347,019
2026-02-03 THOMPSON PETER A Director — 30,953 $44.57 $1,379,866
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
88.98
+26.12%
70.56
+40.18%
50.33
+21.66%
41.37
Research And Development
60.26
+5.19%
57.29
+41.01%
40.63
+17.40%
34.60
Selling General And Administration
28.72
+116.45%
13.27
+36.68%
9.71
+43.45%
6.77
General And Administrative Expense
28.72
+116.45%
13.27
+36.68%
9.71
+43.45%
6.77
Salaries And Wages
18.90
+140.98%
7.84
+32.38%
5.92
+32.11%
4.48
Other Gand A
9.82
+81.00%
5.43
+43.43%
3.78
+65.70%
2.28
Total Expenses
88.98
+26.12%
70.56
+40.18%
50.33
+21.66%
41.37
Operating Income
-88.98
-26.12%
-70.56
-40.18%
-50.33
-21.66%
-41.37
Total Operating Income As Reported
-88.98
-26.12%
-70.56
-40.18%
-50.33
-21.66%
-41.37
EBITDA
-88.33
-26.40%
-69.89
-40.48%
-49.75
-20.61%
-41.25
Normalized EBITDA
-88.33
-26.40%
-69.89
-40.48%
-49.75
-20.61%
-41.25
Reconciled Depreciation
0.65
-3.14%
0.67
+14.58%
0.58
+377.87%
0.12
EBIT
-88.98
-26.12%
-70.56
-40.18%
-50.33
-21.66%
-41.37
Net Income
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Pretax Income
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Net Non Operating Interest Income Expense
13.29
+62.73%
8.17
+195.05%
2.77
+144.61%
1.13
Net Interest Income
13.29
+62.73%
8.17
+195.05%
2.77
+144.61%
1.13
Interest Income Non Operating
13.29
+62.73%
8.17
+195.05%
2.77
+144.61%
1.13
Interest Income
13.29
+62.73%
8.17
+195.05%
2.77
+144.61%
1.13
Other Income Expense
0.42
-39.97%
0.70
+131.89%
0.30
—
Other Non Operating Income Expenses
0.42
-39.97%
0.70
+131.89%
0.30
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Net Income From Continuing Operation Net Minority Interest
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Net Income From Continuing And Discontinued Operation
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Net Income Continuous Operations
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Normalized Income
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Net Income Common Stockholders
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Diluted EPS
—
-1.45
+14.52%
-1.70
+26.76%
-2.32
Basic EPS
—
-1.45
+14.52%
-1.70
+26.76%
-2.32
Basic Average Shares
—
42.44
+52.69%
27.80
+60.38%
17.33
Diluted Average Shares
—
42.44
+52.69%
27.80
+60.38%
17.33
Diluted NI Availto Com Stockholders
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
325.95
+75.48%
185.75
+257.59%
51.95
-40.55%
87.37
Current Assets
241.42
+59.89%
150.99
+285.12%
39.21
-53.23%
83.83
Cash Cash Equivalents And Short Term Investments
235.88
+59.88%
147.54
+283.01%
38.52
-53.37%
82.61
Cash And Cash Equivalents
58.45
+54.68%
37.79
-1.90%
38.52
-29.75%
54.84
Other Short Term Investments
177.43
+61.67%
109.75
0.00
-100.00%
27.77
Other Current Assets
5.54
+60.26%
3.46
+403.64%
0.69
-43.91%
1.22
Total Non Current Assets
84.53
+143.20%
34.76
+172.88%
12.74
+260.24%
3.54
Net PPE
9.15
-11.14%
10.30
-12.22%
11.73
+355.79%
2.57
Gross PPE
11.27
-5.02%
11.87
-6.14%
12.65
+333.38%
2.92
Accumulated Depreciation
-2.12
-35.07%
-1.57
-71.88%
-0.91
-165.70%
-0.34
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.85
+18.01%
0.72
+0.00%
0.72
0.00
Construction In Progress
—
0.00
-100.00%
0.12
-94.96%
2.30
Other Properties
8.50
-8.52%
9.29
-6.64%
9.95
+1513.29%
0.62
Leases
1.92
+3.56%
1.85
+0.00%
1.85
0.00
Investments And Advances
74.42
+262.94%
20.50
0.00
—
Other Non Current Assets
0.96
-75.66%
3.96
+293.24%
1.01
+4.57%
0.96
Total Liabilities Net Minority Interest
19.12
-94.53%
349.46
+109.48%
166.83
+6.06%
157.29
Current Liabilities
11.71
+12.40%
10.42
+29.65%
8.04
-2.62%
8.25
Payables And Accrued Expenses
5.70
-10.65%
6.38
+51.92%
4.20
-33.38%
6.30
Payables
0.77
-35.16%
1.19
+64.95%
0.72
+29.08%
0.56
Accounts Payable
0.77
-35.16%
1.19
+64.95%
0.72
+29.08%
0.56
Current Accrued Expenses
4.93
-5.05%
5.19
+49.22%
3.48
-39.44%
5.74
Pensionand Other Post Retirement Benefit Plans Current
4.74
+59.49%
2.97
-4.50%
3.11
+59.34%
1.95
Current Debt And Capital Lease Obligation
1.27
+18.38%
1.07
+47.25%
0.73
—
Current Capital Lease Obligation
1.27
+18.38%
1.07
+47.25%
0.73
0.00
Other Current Liabilities
0.01
—
—
—
Total Non Current Liabilities Net Minority Interest
7.41
-97.82%
339.05
+113.52%
158.79
+6.54%
149.04
Long Term Debt And Capital Lease Obligation
7.41
-14.62%
8.68
-11.00%
9.75
0.00
Long Term Capital Lease Obligation
7.41
-14.62%
8.68
-11.00%
9.75
0.00
Preferred Securities Outside Stock Equity
0.00
-100.00%
330.37
+121.66%
149.04
+0.00%
149.04
Stockholders Equity
306.83
+287.42%
-163.71
-42.51%
-114.88
-64.29%
-69.92
Common Stock Equity
306.83
+287.42%
-163.71
-42.51%
-114.88
-64.29%
-69.92
Capital Stock
0.04
+800.00%
0.01
+150.00%
0.00
+0.00%
0.00
Common Stock
0.04
+800.00%
0.01
+150.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
-100.00%
149.04
+0.00%
149.04
Share Issued
44.72
+5.37%
42.44
+0.00%
42.44
+0.00%
42.44
Ordinary Shares Number
44.72
+5.37%
42.44
+0.00%
42.44
+0.00%
42.44
Additional Paid In Capital
562.60
+3209.42%
17.00
+276.52%
4.51
+102.92%
2.23
Retained Earnings
-256.35
-41.56%
-181.09
-51.67%
-119.40
-65.52%
-72.14
Gains Losses Not Affecting Retained Earnings
0.54
+46.74%
0.37
0.00
+100.00%
-0.02
Other Equity Adjustments
0.54
+46.74%
0.37
—
-0.02
Total Equity Gross Minority Interest
306.83
+287.42%
-163.71
-42.51%
-114.88
-64.29%
-69.92
Total Capitalization
306.83
+287.42%
-163.71
-42.51%
-114.88
-64.29%
-69.92
Working Capital
229.71
+63.41%
140.57
+350.99%
31.17
-58.76%
75.58
Invested Capital
306.83
+287.42%
-163.71
-42.51%
-114.88
-64.29%
-69.92
Total Debt
8.68
-11.00%
9.75
-6.95%
10.48
0.00
Capital Lease Obligations
8.68
-11.00%
9.75
-6.95%
10.48
0.00
Net Tangible Assets
306.83
+287.42%
-163.71
-42.51%
-114.88
-64.29%
-69.92
Tangible Book Value
306.83
+287.42%
-163.71
-42.51%
-114.88
-64.29%
-69.92
Available For Sale Securities
74.42
+262.94%
20.50
—
—
Investmentin Financial Assets
74.42
+262.94%
20.50
0.00
—
Preferred Stock Equity
—
330.37
+121.66%
149.04
+0.00%
149.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-66.30
-25.59%
-52.79
-20.80%
-43.70
-21.16%
-36.07
Cash Flow From Continuing Operating Activities
-66.30
-25.59%
-52.79
-20.80%
-43.70
-21.16%
-36.07
Net Income From Continuing Operations
-75.27
-22.01%
-61.69
-30.52%
-47.26
-17.45%
-40.24
Depreciation Amortization Depletion
0.65
-3.14%
0.67
+14.58%
0.58
+377.87%
0.12
Depreciation
0.65
-3.14%
0.67
+14.58%
0.58
+377.87%
0.12
Depreciation And Amortization
0.65
-3.14%
0.67
+14.58%
0.58
+377.87%
0.12
Other Non Cash Items
1.96
-81.49%
10.60
+385.39%
2.18
—
Stock Based Compensation
12.07
+225.40%
3.71
+64.14%
2.26
+33.99%
1.69
Change In Working Capital
-2.65
+13.76%
-3.08
-292.72%
-0.78
-128.33%
2.76
Change In Prepaid Assets
-2.08
+24.57%
-2.76
-928.83%
0.33
+144.22%
-0.75
Change In Payables And Accrued Expense
1.56
+0.71%
1.55
+263.88%
-0.94
-126.84%
3.52
Change In Accrued Expense
1.98
+82.87%
1.08
+197.65%
-1.11
-121.98%
5.03
Change In Payable
-0.42
-189.29%
0.47
+188.27%
0.16
+110.70%
-1.51
Change In Account Payable
-0.42
-189.29%
0.47
+188.27%
0.16
+110.70%
-1.51
Change In Other Current Assets
0.00
-100.00%
0.04
0.00
—
Change In Other Current Liabilities
-2.13
-12.18%
-1.90
-1002.91%
-0.17
0.00
Investing Cash Flow
-118.75
+6.43%
-126.91
-564.00%
27.35
+193.47%
-29.26
Cash Flow From Continuing Investing Activities
-118.75
+6.43%
-126.91
-564.00%
27.35
+193.47%
-29.26
Net PPE Purchase And Sale
-0.38
-1296.30%
-0.03
+97.58%
-1.12
+40.45%
-1.87
Purchase Of PPE
-0.38
-1296.30%
-0.03
+97.58%
-1.12
+40.45%
-1.87
Capital Expenditure
-0.38
-1296.30%
-0.03
+97.58%
-1.12
+40.45%
-1.87
Net Investment Purchase And Sale
-118.37
+6.71%
-126.89
-545.71%
28.47
+203.94%
-27.39
Purchase Of Investment
-325.02
-77.76%
-182.84
-676.99%
-23.53
+41.74%
-40.39
Sale Of Investment
206.65
+269.32%
55.95
+7.61%
52.00
+300.00%
13.00
Financing Cash Flow
205.71
+14.94%
178.97
+577212.90%
0.03
-99.97%
110.86
Cash Flow From Continuing Financing Activities
205.71
+14.94%
178.97
+577212.90%
0.03
-99.97%
110.86
Net Common Stock Issuance
202.07
0.00
—
—
Proceeds From Stock Option Exercised
3.64
+2480.85%
0.14
+354.84%
0.03
-51.56%
0.06
Net Other Financing Charges
—
-2.50
—
—
Changes In Cash
20.66
+2919.10%
-0.73
+95.51%
-16.32
-135.84%
45.52
Beginning Cash Position
38.75
-1.86%
39.48
-29.24%
55.80
+443.06%
10.28
End Cash Position
59.41
+53.33%
38.75
-1.86%
39.48
-29.24%
55.80
Free Cash Flow
-66.67
-26.24%
-52.81
-17.85%
-44.81
-18.11%
-37.94
Amortization Of Securities
-3.05
-1.70%
-3.00
-341.97%
-0.68
-69.75%
-0.40
Common Stock Issuance
202.07
0.00
—
—
Issuance Of Capital Stock
202.07
+11.44%
181.33
0.00
-100.00%
110.79
Net Preferred Stock Issuance
0.00
-100.00%
181.33
0.00
-100.00%
110.79
Preferred Stock Issuance
0.00
-100.00%
181.33
0.00
-100.00%
110.79
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category